IMAC (IMAC) Competitors $0.08 +0.00 (+2.50%) As of 09/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock IMAC vs. MYNZ, VYNE, PMCB, SNOA, BIAF, AMIX, GNPX, NLSP, AIM, and CDIOShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Mainz Biomed (MYNZ), VYNE Therapeutics (VYNE), Nuvilex (PMCB), Sonoma Pharmaceuticals (SNOA), bioAffinity Technologies (BIAF), Autonomix Medical (AMIX), GENPREX (GNPX), NLS Pharmaceutics (NLSP), AIM ImmunoTech (AIM), and Cardio Diagnostics (CDIO). These companies are all part of the "medical" sector. IMAC vs. Its Competitors Mainz Biomed VYNE Therapeutics Nuvilex Sonoma Pharmaceuticals bioAffinity Technologies Autonomix Medical GENPREX NLS Pharmaceutics AIM ImmunoTech Cardio Diagnostics IMAC (NASDAQ:IMAC) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends. Do institutionals and insiders have more ownership in IMAC or MYNZ? 24.3% of IMAC shares are held by institutional investors. 10.0% of IMAC shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer IMAC or MYNZ? Mainz Biomed has a consensus target price of $14.00, suggesting a potential upside of 743.37%. Given Mainz Biomed's stronger consensus rating and higher probable upside, analysts clearly believe Mainz Biomed is more favorable than IMAC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is IMAC or MYNZ more profitable? Mainz Biomed has a net margin of 0.00% compared to IMAC's net margin of -75.40%. Mainz Biomed's return on equity of 0.00% beat IMAC's return on equity.Company Net Margins Return on Equity Return on Assets IMAC-75.40% -52.17% -34.51% Mainz Biomed N/A N/A N/A Does the media prefer IMAC or MYNZ? In the previous week, Mainz Biomed had 2 more articles in the media than IMAC. MarketBeat recorded 2 mentions for Mainz Biomed and 0 mentions for IMAC. Mainz Biomed's average media sentiment score of 1.45 beat IMAC's score of 0.00 indicating that Mainz Biomed is being referred to more favorably in the news media. Company Overall Sentiment IMAC Neutral Mainz Biomed Positive Which has preferable valuation & earnings, IMAC or MYNZ? IMAC has higher revenue and earnings than Mainz Biomed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMAC$15.22M0.14-$10.54MN/AN/AMainz Biomed$890K8.54-$21.65M-$65.60-0.03 Which has more risk & volatility, IMAC or MYNZ? IMAC has a beta of -0.88, indicating that its share price is 188% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. SummaryMainz Biomed beats IMAC on 11 of the 14 factors compared between the two stocks. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAC vs. The Competition Export to ExcelMetricIMACSpecialty Outpatient Clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.17M$1.49M$5.85B$10.14BDividend YieldN/AN/A5.68%4.60%P/E RatioN/AN/A75.3425.98Price / Sales0.140.14514.54181.13Price / CashN/AN/A37.5660.44Price / Book0.120.1212.156.29Net Income-$10.54M-$10.54M$3.29B$271.07M7 Day PerformanceN/AN/A0.74%3.87%1 Month PerformanceN/AN/A4.82%4.88%1 Year PerformanceN/AN/A60.58%26.12% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMACIMACN/A$0.08+2.5%N/A-93.5%$2.17M$15.22M0.00106Gap UpMYNZMainz Biomed3.1063 of 5 stars$1.66+1.2%$14.00+743.4%-87.0%$7.60M$890K-0.0330Short Interest ↓VYNEVYNE Therapeutics2.7845 of 5 stars$0.29-1.6%$6.25+2,077.7%-82.7%$7.31M$500K-0.3230News CoverageShort Interest ↓PMCBNuvilex1.5155 of 5 stars$1.07-5.6%N/A-42.5%$7.26MN/A0.414Upcoming EarningsShort Interest ↑Gap DownHigh Trading VolumeSNOASonoma Pharmaceuticals0.7912 of 5 stars$4.36-4.6%N/A+41.0%$7.16M$14.91M-1.77180BIAFbioAffinity Technologies0.3079 of 5 stars$0.25+1.2%N/A-83.6%$7.06M$9.36M-0.3510AMIXAutonomix Medical2.4258 of 5 stars$1.19+1.7%$5.00+320.2%-93.5%$7.05MN/A-0.211Short Interest ↓GNPXGENPREX1.2371 of 5 stars$0.21+1.6%N/A-31.6%$6.99MN/A0.0020News CoverageShort Interest ↑NLSPNLS PharmaceuticsN/A$1.94-2.0%N/A+1,528.8%$6.98MN/A0.006Short Interest ↓AIMAIM ImmunoTech1.4858 of 5 stars$2.57-0.8%$275.00+10,600.4%-91.3%$6.96M$121K-5.4720Gap DownCDIOCardio Diagnostics1.4733 of 5 stars$3.95+8.8%N/A-56.6%$6.95M$40K0.001 Related Companies and Tools Related Companies Mainz Biomed Competitors VYNE Therapeutics Competitors Nuvilex Competitors Sonoma Pharmaceuticals Competitors bioAffinity Technologies Competitors Autonomix Medical Competitors GENPREX Competitors NLS Pharmaceutics Competitors AIM ImmunoTech Competitors Cardio Diagnostics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAC) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
